These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 31651448)

  • 21. Three Recent Cases of Likely Methadone Cross-Reactivity With Vortioxetine.
    Kieran K
    J Am Psychiatr Nurses Assoc; 2019; 25(3):170. PubMed ID: 31117909
    [No Abstract]   [Full Text] [Related]  

  • 22. Augmentation of Cognitive Training With Vortioxetine Opens New Avenues for Targeting Age-Related Changes in Brain Connectivity.
    Jaywant A
    Am J Geriatr Psychiatry; 2023 Jun; 31(6):398-400. PubMed ID: 36828690
    [No Abstract]   [Full Text] [Related]  

  • 23. [Role of cAMP/CREB/BDNF signaling pathway in anti-depressive effect of vortioxetine in mice].
    Yu H; Chen JJ; Zeng BQ; Zhong QP; Xu JP; Liu YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan; 37(1):107-112. PubMed ID: 28109109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vortioxetine treatment-emergent mania in the elderly: a case report.
    D'Andrea G; De Ronchi D; Giaccotto L; Albert U
    Australas Psychiatry; 2019 Aug; 27(4):413. PubMed ID: 31328985
    [No Abstract]   [Full Text] [Related]  

  • 25. Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study.
    Adamo D; Pecoraro G; Aria M; Favia G; Mignogna MD
    Pain Med; 2020 Jan; 21(1):185-194. PubMed ID: 31343684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex.
    du Jardin KG; Müller HK; Sanchez C; Wegener G; Elfving B
    Eur J Pharmacol; 2016 Sep; 786():29-35. PubMed ID: 27235984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paroxetine
    Callegari C; Ielmini M; Caselli I; Lucca G; Isella C; Diurni M; Pettenon F; Poloni N
    Psychopharmacol Bull; 2019 Feb; 49(1):28-43. PubMed ID: 30858637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter.
    Andersen J; Ladefoged LK; Wang D; Kristensen TN; Bang-Andersen B; Kristensen AS; Schiøtt B; Strømgaard K
    ACS Chem Neurosci; 2015 Nov; 6(11):1892-900. PubMed ID: 26389667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
    Christensen MC; Florea I; Lindsten A; Baldwin DS
    J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vortioxetine for the treatment of depression.
    Pearce EF; Murphy JA
    Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute dosing of vortioxetine strengthens event-related brain activity associated with engagement of attention and cognitive functioning in rats.
    Laursen B; Bundgaard CH; Graversen C; Grupe M; Sanchez C; Leiser SC; Sorensen HBD; Drewes AM; Bastlund JF
    Brain Res; 2017 Jun; 1664():37-47. PubMed ID: 28366617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
    Meeker AS; Herink MC; Haxby DG; Hartung DM
    Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium.
    Chen G; Nomikos GG; Affinito J; Zhao Z
    Clin Pharmacokinet; 2016 Sep; 55(9):1115-27. PubMed ID: 27048210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine.
    Lachaine J; Beauchemin C; Bibeau J; Patenaude J; Chokka P; Proulx J; Bougie J
    CNS Spectr; 2020 Jun; 25(3):372-379. PubMed ID: 31120009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling.
    Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
    J Affect Disord; 2016 Jan; 190():357-361. PubMed ID: 26546771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.